CATX Stock Analysis: Buy, Sell, or Hold?
CATX - Perspective Therapeutics, Inc.
$3.85
-0.05 (-1.28%)
▼
5d:
-14.63%
30d:
-12.9%
90d:
+1.58%
HOLD
MODERATE Confidence
Analysis Updated: May 1, 2026 12:00 AM ET
Earnings: May 11, 2026
7d
Smart Money Accumulation
CATX is down 14.3% this week, but smart money is accumulating calls. Top strike: $5 2026-07-17 with 2,544 OI. Call ratio: 87% View Scanner →
Strength: 10.0/10
Get Alerted When CATX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CATX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CATX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CATX is currently trading at $3.85, which is considered oversold relative to its 30-day fair value range of $4.11 to $4.53.
Technical Outlook: Technically, CATX is in a strong uptrend. The price is currently testing key support at $3.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CATX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.00 (+237.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CATX is in a strong uptrend. The price is currently testing key support at $3.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CATX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.00 (+237.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.11 -
$4.53
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 237.7% below Wall St target ($13.00)
- CAUTION: 5-day price weakness (-14.6%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$4.11 -
$4.53
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.77
Resistance Level
$4.87
Current Trend
Strong Uptrend
Technical data as of
May 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.28
Wall Street Target
$13.00
(+237.7%)
Revenue Growth (YoY)
-43.4%
Share & Embed Analysis
Last updated: May 02, 2026 8:59 PM ET
Data refreshes hourly during market hours. Next update: 9:59 PM
Data refreshes hourly during market hours. Next update: 9:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CATX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jonathan Robert Hunt
BUY
11000 shares
2025-11-13
Robert F Williamson III
BUY
9498 shares
2025-11-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$86 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$87 | 52 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 53 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$419 | 42 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 65 BUY |
